Related Experiment Video

Updated: Jul 30, 2025

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.2K

Dasatinib: a potential tyrosine kinase inhibitor to fight against multiple cancer malignancies

Fauziya1, Akash Gupta1, Arif Nadaf1

  • 1Department of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi, 110062, India.

Medical Oncology (Northwood, London, England)
|May 10, 2023
PubMed

Insights

Dasatinib, a potent second-generation Tyrosine Kinase Inhibitor (TKI), offers a promising therapeutic strategy for various leukemias and cancers. This review details its methodology, pharmacokinetics, and clinical considerations for enhanced cancer treatment.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Cancer remains a leading global cause of mortality, necessitating innovative therapeutic approaches.
  • Second-generation Tyrosine Kinase Inhibitors (TKIs) represent a significant advancement in cancer treatment.
  • Dasatinib exhibits 300-fold greater potency compared to imatinib, highlighting its therapeutic potential.

Purpose of the Study:

  • To comprehensively review and evaluate dasatinib as a therapeutic agent.
  • To enhance understanding of dasatinib's therapeutic methodology, pharmacodynamics, and pharmacokinetics.
  • To consolidate information on dasatinib's side effects, benefits, drawbacks, interactions, and novel formulations.

Main Methods:

  • Literature review and evaluation of existing dasatinib research.
  • Analysis of dasatinib's pharmacological properties and clinical data.
  • Synthesis of information regarding dasatinib's therapeutic applications and formulation advancements.

Main Results:

  • Dasatinib demonstrates significant potency and broad applicability in treating various leukemias and cancers.
  • Detailed insights into dasatinib's absorption, distribution, metabolism, and excretion (pharmacokinetics) were compiled.
  • A thorough examination of dasatinib's efficacy, safety profile, drug interactions, and formulation development was conducted.

Conclusions:

  • Dasatinib is a potent second-generation TKI with significant therapeutic potential in oncology.
  • This review provides a consolidated knowledge base for dasatinib's clinical application and future development.
  • Understanding dasatinib's comprehensive profile is crucial for optimizing its use in cancer therapy.
Keywords:
BioavailabilityCancerDasatinibFormulationsSide effectsSolubilityTyrosine kinase inhibitor

More Related Videos

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays07:42

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

8.0K
Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

7.9K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
215
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.6K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.0K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K